natgillin/translations-raw huggingface dataset:
A compound of formula I, or a salt thereof, for use in the treatment of a disease or condition comprising inhibiting an immune response, wherein formula I is: wherein n is I; 
PATENTNI ZAHTJEVI Spoj formule I, ili njegova sol, namijenjen upotrebi u liječenju bolosti ili stanja koje se sastoji u inhibiranju imunosnog odgovora, gdje formula I je: mx
or A is selected from 
A je odabran od sljedećih:
Fig. 3 is a perspective view of the parts making up the building wall of Figs. 
je prostorni pogled dijelova koji tvore zid građevine sa slika 112.
a first amino acid sequence comprising amino acids 1 through 215 of human osteoprotegerin (GenBank: U94332.1); and a second amino acid sequence comprising amino acids 103 through 329 of human immunoglobulin gamma-1 Fc (GenBank: J00228.1), wherein said polypeptide is capable of inhibiting RANKL-induced osteoclast differentiation in an in vitro cell-based assay with an EC50 of 50 ng/ml or to no more than 10% at a concentration of 100 ng/ml. 
prvu sekvencu aminokiseline koja sadrži aminokiseline 1 do 215 ljudskog osteoprotegerina (GenBank: U94332.1); i drugi niz aminokiselina koji sadrži aminokiseline 103 do 329 humanog imunoglobulina gama-1 Fc (GenBank: J00228.1), pri čemu je navedeni polipeptid sposoban inhibirati diferencijaciju osteoklasta uzrokovanu RANKL u in vitro ispitivanju zasnovanom na stanicama s EC50 od 50 ng / ml ili do ne više od 10% u koncentraciji od 100 ng / ml.
The rat LH Time-Resolved Immuno Fluorometric Assay (TR-IFMA) has been developed in house using home made reagents, a monoclonal catching antibody directed against the B-subunit of human chorion gonadotrophin (hCG, which cross reacts with rat B-subunit) and a biotin labelled detecting antibody (rabbit polydonal antibody directed against the alfa-subunit of recombinant rat LH). 
U našoj kući razvijeno je Vremenski ovisno imunofluorimetrijsko ispitivanje štakorskog LH (TR-IFMA), pomoću reagensa iz kućne radinosti, monoklonskog uhvatnog protutijela protiv B-podjedinice ljudskog korionskog gonadotrofina (hCG, koji ukriženo reagira sa štakorskom B-podjedinicom) i biotinom obilježenog detekcijskog protutijela (kunićje poliklonsko protutijelo protiv a-podjedinice rekombinantnog štakorskog LH).
The receptacle (100; 200; 400; 500) for containing and dispensing solid medicinal pills according to claim 1, wherein said sealing closure (112; 212; 412; 512) is maintained in its closed position by interengagement with a frame (114) provided inside said outlet (106; 506). 
Spremnik (100; 200; 400; 500), namijenjen držanju 1 izdavanju čvrstih medicinskih pilula u skladu s patentnim zahtjevom 1, gdje se navedeni hermetički zatvarač (112; 212; 412; 512) drži u svom zatvorenom položaju međudjelovanjem s okvirom (114) koji se nalazi unutar navedenog izlaza (106; 506).
Hallucinations are defined as sensory perception in the absence of external stimuli. 
Halucinacije su definirane kao osjetilna percepcija u odsutnosti vanjske stimulacije.
The flexible container is interposed between the suction cups installed on the movable head and the suction cups buried within the support plane. 
Savitljivi spremnik se stavi između usisnih čašica koje su postavljene na pokretnu glavu i usisnih čašica koje su umetnute u potpornu plohu.
The container of claim 22, comprising from about 1 ml to about 5 ml of the solution. 
Posuda iz patentnog zahtjeva 22, obuhvaća od oko 1 ml do oko 5 ml rastvora.
82% to 83% by weight of microcrystalline cellulose; 
(i) 82% do 83% po masi mikrokristalne celuloze;
Anti-Drug Antibodies directed against said therapeutic antibody; to obtain a patient profile, wherein the patient profile indicates the responsiveness to said treatment, and wherein the ADA are detected according to the method of claim 1. 
- - protutijela na lijek usmjerenog naspram navedenog terapijskog protutijela; zbog dobivanja profila pacijenta, pri čemu profil pacijenta ukazuje na odgovor na navedeno liječenje i pri čemu su ADA detektirana u skladu s metodom iz patentnog zahtjeva 1.
A viral vector according to claim 9, wherein said (auto)protease is the foot and mouth disease virus (FMDV) autoprotease 2A. 
Viralni vektor prema patentnom zahtjevu 9, naznačen time da navedena (auto)proteaza jest autoproteaza 2 virusa slinavke i šapa (EMDV, prema engl.,,f0ot and mouth disease virus").
The computer-readable medium of claim 8 having further executable instructions, that when executed, perform the step of filtering the qd feedback signal. 
Računalno čitljivi medij u skladu s patentnim zahtjevom 8, naznačen time, da ima daljnje izvršne upute, da kada se izvrši, izvršiti korak filtriranja qd povratnog signala (704).
is halogen, perhaloalkyl, CN, SR5, NHR5, N(R5)2, aryl, or heteroaryl, wherein said aryl is optionally substituted with up to two substituents selected from C1-8 alkyl, halogen, perhalo alkyl, and alkoxy, and said heteroaryl is optionally substituted with up to two substituents selected from halogen and C1-8 alkyl; and 
Rs je halogen, perhaloalkil, CN, SRs, NHRs, N(Rs),, aril ili heteroaril pri čemu je navedeni aril po izboru supstituiran sve do sa po dva supstituenda izabrana iz skupine koju čine C,.galkil, halogen, perhaloalkil i alkoksi te je navedeni heteroaril po izboru supstituiran sve do sa po dva supstituenda izabrana iz skupine koju čine halogen i Ci.salkil; te
adding at least one water soluble lithium compound to the aqueous preparation in an amount such that the total amount of solubilised lithium in the aqueous preparation is from 1000 to 3000 ppm, calculated relative to the weight of water in the preparation, where steps (a) and (b) may be carried out simultaneously, or separately in any order and wherein the stabilization leads to a reduction of the cfu/ml value to a value of less than 104 cfu/ml, wherein the at least one water soluble lithium compound is a polymeric salt of lithium selected from the group consisting of acrylic homopolymers, acrylic copolymers such as copolymers of acrylic acid and maleic acid and/or acrylamide. 
barem jedan izvor u vodi topljivog spoja litija odabran iz skupine koju čine neorganske i/ili organske litijeve soli, litijeve baze i njihove smjese, te je poželjno odabran od litijevog klorida i/ili litijevog karbonata i/ili litijevog hidroksida, u količini tako da je ukupna količina otopljenog litija u vodenom pripravku od 1000 do 3000 ppm, izračunato u odnosu na težinu vode u pripravku; kao biocidnog pripravka u vodenom pripravku koji sadrži sojeve bakterija odabrane iz skupine koju čine Metilobacteria i Pseudomonas koje su rezistentne na, tolerantne na i/ili degradiraju biocide koji oslobađaju aldehid i/ili biocide s jednom ili više aldehidnih skupina u odsutnosti litijevih iona.
This aspect of the invention also extends to: 
Datum objave europske prijave patenta:
A pharmaceutical composition comprising a compound of any of claims 1-18 and a pharmaceutically acceptable carrier. 
Farmaceutski sastav obuhvaća tvar iz bilo kojeg od patentnih zahtjeva 1-18 1 farmaceutski prihvatljivi nosač.
is a linker connected to a modulator or fragment or derivative thereof; Q is selected from 0, S and NH; 
R'" je poveznica spojena na protutijelo anti-DLL3; Q je odabran od O, SiNH, poželjno gdje Q je O;
is C1-C10alkyl, C3-C7cycloalkyl or phenyl-C1-C6alkyl, wherein the phenyl moiety in phenyl or phenyl-C1-C6akyl is optionally substituted with 1, 2 or 3 substituents each independently selected from hydroxy, C1-C6alkoxy, amino, mono- and diC1-C6alkylamino; or a pharmaceutically acceptable salt or solvate thereof. 
R? je Ci-Croalkil, C3-Czcikloalkil ili fenil-C;-Cgalkil, pri čemu fenilni dio u fenilu ili fenil-C,-Cgakilu je proizvoljno supstituiran sa 1, 2 ili 3 supstituenta koji su svaki neovisno odabrani od hidroksi, C;-Cgalkoksi, amino, mono- i diCy-Cgalkilamino; ili njihova farmaceutski prihvatljiva soli ili solvat.
The process according to any one of the preceding claims, characterized in that the filler and/or pigment is associated with dispersing agents selected from the group comprising homopolymers or copolymers of polycarboxylic acid salts based on, e.g., acrylic acid, methacrylic acid, maleic acid, fumaric acid, itaconic acid, acryl amide or mixtures thereof; alkali polyphosphates, phosphonic-, citric- and tartaric acids and the soluble salts thereof; or mixture thereof 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što su punilo i/ili pigment pomiješani s disperzijskim sredstvima, koja se bira iz skupine koju čine homopolimeri ili kopolimeri polikarboksilnih kiselina i/ili njihovih soli ili derivata, poput estera na bazi, primjerice, akrilne kiseline, metakrilne kiseline, maleinske kiseline, fumarne kiseline, itakonske kiseline, primjerice amida ili estera akrilne kiseline, poput metil-metakrilata, ili njihovih smjesa; alkalni polifosfati, fosfonska, limunska i vinska kiselina i njihove soli ili esteri; ili njihove smjese.
wherein the affinity of the antibody in its bivalent form to human CD79b is substantially the same as or at least 2, 3, 4, 5, 6, 7, 8, 9 or 10-fold greater than the affinity of a murine or chimeric antibody comprising a light chain and heavy chain variable sequence of SEQ ID NO: 10 and SEQ ID NO: 14 in its bivalent form, wherein the binding affinity is expressed as a Kd value, and wherein the binding affinity is measured by Biacore or radioimmunoassay. The antibody of claim 1 or claim 2, which binds to the same epitope as a monoclonal antibody comprising the variable domains of SEQ ID No:10 and SEQ ID No:14. 
HVR-H3 koja sadrži sekvencu F1-F10, gdje F1-F10 je TRRVPIRLDY (SEQ ID NO: 204); pri čemu se protutijelo veže na isti epitop kao i monoklonalno protutijelo koje sadrži varijabilne domene od SEQ ID No. 10 i SEQ ID No. 14, protutijelo koje sadrži varijabilne domene od SEQ ID No. 207 i SEQ ID No. 208 ili protutijelo koje sadrži sekvencu slabog lanca od SEQ ID No. 307 i sekvencu jakog lanca od SEQ ID No. 308.
means (102) for encoding Physical Layer Pipe, PLP, data for carrying at least one service; 
sredstvo (301, 303) za kodiranje podataka cijevi fizičke razine, PLP, za prijenos barem jednog servisa;
SEQ ID NO:5 - huMov19 vLCv1.60 An anti-Folate receptor 1 (FOLR1) antibody or anti-FOLR1 immunoconjugate for use in cancer therapy in a subject, wherein an increased expression of FOLR1 gene or protein in a cancer sample from said subject has been detected using a detection method that distinguishes between staining intensity or staining uniformity in a FOLR1 expressing cancer sample as compared to staining intensity or staining uniformity in one or more reference sample, wherein the efficacy of cancer therapy with an anti-FOLR1 antibody or anti-FOLR1 immunoconjugate has thereby been increased; 
Protutijelo protiv Folatnog receptora 1 (FOLRI1) ili imunokonjugat protiv FOLR1, namijenjeni upotrebi u terapiji raka kod subjekta, gdje je pojačano eksprimiranje gena za FOLRI1 ili proteina u uzorku raka iz navedenog subjekta detektirano postupkom detektiranja koji razlikuje između intenziteta bojanja ili jednoličnosti bojanja u uzorku raka koji eksprimira FOLR1 u usporedbi s intenzitetom bojanja ili jednoličnošću bojanja u jednom ili više referentnih uzoraka, čime je povećana djelotvornost terapije raka protutijelom protiv FOLRI1 ili imunokonjugatom protiv FOLR1; naznačeni time što protutijelo protiv FOLR1, namijenjeno upotrebi u terapiji raka, sadrži:
In another embodiment, the chromatography is selected from the group consisting of Hydrophobic Interaction Chromatography (HIC), Ion Exchange chromatography (IEC), Size exclusion chromatography (SEC), Affinity chromatography, and Reversed-phase chromatography. 
Postupak prema zahtjevu 18, pri čemu je kromatografija odabrana od skupine koja se sastoji od kromatografije hidrofobnih interakcija (HIC), ionoizmjenjivačke kromatografije (IEC), kromatografije isključenjem po veličini so
The mixture was stirred at 50° C. for 16 hours. THF was removed in vacuo, the aq. solution was washed with ether, and cooled at 0° C. Neutralization with 10% aq. citric acid (26.0 mL, 40.6 mmol) gave a precipitate, which was washed with H2O and dried to give compound 5-1 (1.88 g, 82%). 
Smjesu se miješa 16 sati na 50 *C. THF se ukloni u vakuumu, vodenu otopinu ispere eterom, te ohladi na 0 *C. Neutraliziranjem 10 %-tnom vodenom otopinom limunske kiseline (26,0 ml, 40,6 mmol) dobije se talog, kojeg se ispere s H20, te osuši kako bi se dobilo spoj 5-1 (1,88 g, 82 %).
The method of clause 7, wherein the compactin batch of step c) comprises less than about 0.15% compactin C by weight. 
Postupak prema zahtjevu 6, naznačen time što scrija kompaktina iz koraka c) sadrži manje od 0.15% ukupne mase kompaktina C.
The method according to claim 12, wherein the dosimeter is at least one of a point dosimeter, a linear array of point dosimeters, a two-dimensional array of point dosimeters, a three-dimensional array of point dosimeters, and at least one two-dimensional dosimeter. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time što je dozimetar najmanje jedan od točkastog dozimetra, linearnog niza točkastih dozimetara, dvodimenzionalnog niza točkastih dozimetara, trodimenzionalnog niza točkastih dozimetara, i najmanje jedan dvodimenzionalni dozimetar.
an immunologically effective amount of an isolated polypeptide comprising (a) an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 182 and/or (b) a fragment of SEQ ID NO: 182, wherein the fragment of SEQ ID NO: 182 comprises 16 or more consecutive amino acids of the amino acid sequence of SEQ ID NO: 182; wherein the concentration of each isolated polypeptide is at least 1 g/ml. 
Cjepivo, naznačeno time što sadrži antigen sta006 i adjuvans, gdje antigen sta006 sadrži aminokiselinski slijed: (i) (a) koji je 70% ili više istovjetan SEQ ID NO: 42; i/ili (b) sadrži fragment od najmanje n uzastopnih aminokiselina iz SEQ ID NO: 42, gdje je n 7 ili više; i (ii) gdje antigen sta006 može dovesti do proizvodnje protutijela koje prepoznaje SEQ ID NO: 42.
A method, according to claim 12 or 13, wherein in the case of the monitoring of areas provided with level crossings, the acquisition of images and transmission of them is foreseen in correspondence of the passing the train, acquiring, a closure signal of the bars. 
Postupak, prema zahtjevu 12 ili 13, naznačen time da je u slučaju nadzora lokacija predviđenih s prijelazima u razini vlaka, dobivanje slika i njihov prijenos predviđen u skladu s prolaskom vlaka, čime se dobiva, signal zatvaranja rampe.
The solid oral dosage form according to any one of claims 1 to 4, wherein the oral dosage form provides a rate of absorption of valsartan free acid with a tmax of 1 to 2.2 h following administration of a single dose of said dosage form. 
Čvrsti oralni dozni oblik prema zahtjevu 1, naznačen time, da oralni dozni oblik omogućava brzinu resorpcije kiseline bez valsartana, koja iznosi tmax od 1 do 2,2 sata nakon davanja jednostruke doze navedenog doznog oblika.
The extended release dosage form of claim 11, wherein the opioid analgesic is oxycodone hydrochloride and the dosage form comprises from about 5 mg to about 500 mg of oxycodone hydrochloride, preferably 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 45 mg, 60 mg, or 80 mg, 90 mg, 120 mg or 160 mg of oxycodone hydrochloride. 
Postupak prema zahtjevu 39, naznačen time da je opioidni analgetik oksikodon hidroklorid i da oblici davanja sadrže od oko 5 mg do oko 500 mg oksikodon hidroklorida. Postupak prema zahtjevu 40, naznačen time da oblik davanja sadrži 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 45 mg, 60 mg, or 80 mg, 90 mg, 120 mg ili 160 mg oksikodon hidroklorida.
The device according to claim 2, characterized in that the means for pressing the middle portion of the nail are mounted pivotably in the first support, and a pressing force is adjustable by a screw for regulating the pressing of the nail. 
Naprava prema zahtjevu 2, naznačena time što je poluga (121; 221) za pritiskanje nokta montirana zakretno pomično u prvom nosaču (102; 202), i što se sila pritiska može podešavati pomoću vijka (123; 223) za regulaciju pritiska na nokat.
The container according to claim 1 or 2, wherein the fluid guide element (16, 17, 18, 36, 37, 38, 39, 40, 41) provides the function of distributing the adhesive to desired locations in the panel (27, 29, 31). 
Spremnik u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je navodeći element za fluid (16, 17, 18) lokalno udubljenje načinjeno užljebljivanjem.
The separation element can be integral with at least one of the body and the cover. It can also be a separate item interposed between the body and the cover. 
Uređaj prema jednom od patentnih zahtjeva 1 do 8, pri čemu je element (1) odvajanja integralan sa najmanje jednim od tijela i poklopcem.
rapidly lowering the pH of the reaction mixture to a pH of less than 2 by addition of nitric acid; wherein, the isolated monomeric platinum complex has a formula of II or IV as set forth in FIG. 1; 
(iv) brzo snižavanje pH reakcijske smjese na pH od manje od 2 dodavanjem dušične kiseline; pri čemu izolirani monomerni kompleks pina (IV) ima formulu II ili IV:
It can be noted in Figures 5 and 6 that apertures 9 extending through the attachment portion 2" are formed in the flexible and bending resistant attachment portion 2" in the portion 10" protruding into the data portion. 
Na slikama 5 i 6 se može primijetiti da su otvori 9, koji se pružaju kroz predio za povezivanje 2", načinjeni u predjelu za povezivanje 2", koji je u predjelu 10", i koji je otporan na pregibanje i na savijanje, a koji strši u predio za podatke.
Formulations for injection may be presented in unit dose form in ampoules, or in multidose containers with an added preservative. 
Injekcijske formulacije može se davati u obliku jedinice doze, u ampulama, ili u višedoznim spremnicima, uz dodatak konzervansa.
Phosphatidylcholine for use in the method of claim 7, wherein said phosphatidylcholine is administered in a delayed release oral formulation, wherein, preferably, the delayed release is pH-dependent, wherein, preferably, the pH-dependent delayed release formulation comprises a gastric acid resistant substance, wherein the gastric acid resistant substance is preferably selected from the group consisting of film covershields and carrier matrices, or wherein the gastric acid resistant substance comprises preferably acrylpolymers, wherein said acrylpolymer is preferably Eudragit, more preferably Eudragit S 100 or Eudragit L30, wherein, preferably, the pH-dependent delayed release oral formulation comprises about 500 mg phosphatidylcholine. 
Fosfatdilkolin za uporabu u postupku prema zahtjevu 7, naznačen time, da se spomenuti fosfatdilkolin primjenjuje kao oralna formulacija s odgođenim otpuštanjem, pri čemu je poželjno da je odgođeno otpuštanje ovisno o pH-vrijednosti, pri čemu je poželjno da formulacija s odgođenim otpuštanjem ovisnim o pH-vrijednosti, sadrži tvar otpornu na želučanu kiselinu, gdje je tvar koja je otporna na želučanu kiselinu poželjno odabrana iz skupine koju čine zaštitni film-omotači 1 matrice-nosači, ili gdje tvar otporna na želučanu kiselinu sadrži poželjno akrilpolimere, pri čemu spomenuti akrilpolimer je poželjno Eudragit, još bolje Eudragit S100 ili Eudragit L30, dok oralna formulacija koja ima odgođeno otpuštanje ovisno o pH-vrijednosti, poželjno sadrži oko 500 mg fosfatdilkolina.
A process for preparing a compound of the formula I wherein 
Postupak dobivanja spoja formule I gdje
In addition in a further configuration it is proposed that with a falling wind speed in the transition from the full-load mode of operation to the part-load mode of operation the power is firstly reduced, in particular for a predetermined wind speed range, while the rotary speed is kept constant. 
Postupak prema zahtjevu 1, naznačen time da se s opadanjem brzine vjetra pri prijelazu iz režima rada s punim opterećenjem u režim rada s djelomičnim opterećenjem, prvo smanjuje snaga, posebno za unaprijed određene opsege brzine vjetra, pri čemu se brzina rotacije održava konstantnom.
The compounds of Set A are meant to further illustrate the scope of the invention without being limiting in any way. 
Spojevi Skupine A imaju za namjeru dalje opisati doseg izuma bez ograničavanja na bilo koji način.
The system according to any one of claims 6 - 10, wherein the medical device is adapted to rest against the outside of the stomach wall without restricting the food passage in the food passageway. 
Uređaj u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što je uređaj prilagođen da bude u najmanju ruku djelomično invaginiran u stijenku želuca međuželučanim kopčama, s vanjske strane stijenke želuca.
The way in which sheet 22 of wrapping is folded about group 4 of cigarettes is shown in FIGS. 7, 8 and 9, and comprises first folding sheet 22 of wrapping into a U about group 4 of cigarettes to cover a top wall of group 4 of cigarettes defined by the filters of the cigarettes in group 4, and the front and rear walls of group 4 of cigarettes defined by the cylindrical lateral walls of the cigarettes in group 4 . 
HR P20120149 T1 PATENTNI ZAHTJEVI Pakiranje cigareta koje sadrži: skupinu (4) cigareta, na kojem je gornja stijenki određena filtrima cigareta, donja stijenki vršcima cigareta, prednje i stražnje stijenki cilindričnim bočnim stjenkama cigareta, te manje bočne stjenke koje su određene cilindričnim bočnim stjenkama cigareta; unutarnje pakiranje (3) u koje je umetnuta skupina (4) cigareta, a izrađeno je od lista
A compound of formula (XIV): wherein: Ra and RB are, independently of one another, a hydrogen atom or a (C1-C6)alkyl group or together form, with the carbon atom which bears them, a 3- to 5-membered carbocycle; 
Spoj s formulom (XIV): [image] naznačen time da: Ra i RB su, međusobno neovisno, vodikov atom ili (C1-C6)alkil skupina ili zajedno tvore, s ugljikovim atomom koji ih nosi, 3- do 5-člani karbocikal;
is an optionally substituted monocyclic or bicyclic aryl or heteroaryl, wherein each ring is a 5, 6 or 7 membered ring and the optional substitution is halo, cyano, C1-C6 alkyl, C1-C6 branched alkyl, halogenated C1-C6 alkyl, hydroxyl, C1-C6 alkyloxy, amino, or C1-C6 alkylamino; and 
D, je opcionalno supstituirani monociklički ili biciklički aril ili heteroaril, pri čemu je svaki prsten 5, 6 ili 7 člani prsten i opcionalna supstitucija je halo, cijano, C,-C4 alkil, Ci-Cg razgranati alkil, halogenirani C,-Cg alkil, hidroksil, Ci-Cg alkoksi, amino ili Ci-Cg alkilamino; i
A system according to Claim 1, wherein the receiver includes means for actuating an alarm when wireless communication between the transmitter and the receiver is broken. 
2, Sustav u skladu s patentnim zahtjevom 1, naznačen time da prijemnik sadrži način za pokretanje alarma kad je prekinuta bežična komunikacija između odašiljača i prijemnika.
A method according to claim 1, further comprising the concentrator transmitting values indicating storage locations to the one remote meter requesting transmission of utility consumption related data stored in the storage locations indicated by said values. 
Metoda prema bilo kojem od patentnih zahtjeva 1 do 4, pri čemu sabirnik (C) prenosi vrijednosti koje označuju lokacije za pohranu do daljinskog brojača (RM) zahtijevajući prijenos navedenih periodički izmjerenih i pohranjenih podataka vezanih uz potrošnju pohranjenih na lokacijama za pohranu označenim navedenim vrijednostima.
"Treating" refers to mediating a disease or condition, and preventing or mitigating its further progression or ameliorating the symptoms associated with the disease or condition. 
"Liječenje" se odnosi na posredovanje kod bolesti ili stanja, te na sprječavanje ili usporavanje njegovog daljnjeg napredovanja ili ublažavanje simptoma povezanih s bolešću ili stanjem.
—O—C1-6alkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl, 
(5) - -O-Crsalkil, koji je nesupstituiran ili supstituiran sa halogenom, hidroksil ili fenil,
hydrogenating the compound of Formula LIX to give a compound of Formula LX; 
-B(OH)2 Formula XV čime se dobiva spoj Formule LIX:
The resulting cell concentration in the TCF reached approximately 0.20 million cells/mL. 
Time je koncentracija stanica u TCF dosegla približno 0.20 milijuna stanica/mL.